441 related articles for article (PubMed ID: 28464704)
1. Prospects for new and emerging therapeutics in severe asthma: the role of biologics.
Kepil Özdemir S; Bavbek S
Expert Rev Respir Med; 2017 Jun; 11(6):505-512. PubMed ID: 28464704
[TBL] [Abstract][Full Text] [Related]
2. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
3. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
4. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
Santus P; Saad M; Damiani G; Patella V; Radovanovic D
Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
[TBL] [Abstract][Full Text] [Related]
5. Role of Biologics in Asthma.
McGregor MC; Krings JG; Nair P; Castro M
Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
7. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
Bakakos A; Loukides S; Usmani OS; Bakakos P
Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
[TBL] [Abstract][Full Text] [Related]
8. Biologic and New Therapies in Asthma.
Tabatabaian F; Ledford DK; Casale TB
Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
[TBL] [Abstract][Full Text] [Related]
9. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
10. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
Mavissakalian M; Brady S
Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
Walsh GM
Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
[TBL] [Abstract][Full Text] [Related]
12. The use of biologics in personalized asthma care.
Watchorn D; Holguin F
Expert Rev Clin Immunol; 2021 Dec; 17(12):1301-1309. PubMed ID: 34767743
[TBL] [Abstract][Full Text] [Related]
13. Choice of biologics in asthma endotypes.
Wangberg H; Woessner K
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
[TBL] [Abstract][Full Text] [Related]
14. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
15. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent.
Krings JG; McGregor MC; Bacharier LB; Castro M
J Allergy Clin Immunol Pract; 2019; 7(5):1379-1392. PubMed ID: 31076056
[TBL] [Abstract][Full Text] [Related]
16. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
Sabbe M; Schleich F; Janssens P; Louis R
J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
18. Current Biologics in Asthma Treatment.
Imanirad D; Tabatabaian F
Semin Respir Crit Care Med; 2022 Oct; 43(5):627-634. PubMed ID: 36220056
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of biologics for asthma treatment by allergy specialists: A questionnaire survey.
Kuruvilla M; Ariue B; Oppenheimer JJ; Singh U; Bernstein JA
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):433-439. PubMed ID: 32629016
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]